Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.58
(-0.83%)
CNY 3.58
(-0.83%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 276.22 Million CNY | -4.79% |
| 2022 | 228.42 Million CNY | -14.75% |
| 2021 | 267.92 Million CNY | -13.98% |
| 2020 | 311.46 Million CNY | 53.27% |
| 2019 | 203.21 Million CNY | 2.94% |
| 2018 | 197.41 Million CNY | -13.52% |
| 2017 | 228.26 Million CNY | -6.87% |
| 2016 | 245.11 Million CNY | 2.65% |
| 2015 | 238.79 Million CNY | 35.5% |
| 2014 | 176.23 Million CNY | 38.42% |
| 2013 | 127.31 Million CNY | 41.64% |
| 2012 | 89.89 Million CNY | 31.77% |
| 2011 | 68.21 Million CNY | 38.96% |
| 2010 | 49.09 Million CNY | 23.67% |
| 2009 | 39.69 Million CNY | 52.34% |
| 2008 | 26.05 Million CNY | 29.52% |
| 2007 | 20.11 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 61 Million CNY | 65.41% |
| 2024 Q2 | 39.17 Million CNY | 1.97% |
| 2024 Q1 | 38.42 Million CNY | -14.63% |
| 2023 Q2 | 56.24 Million CNY | -2.89% |
| 2023 Q3 | 58.32 Million CNY | 3.69% |
| 2023 Q4 | 45 Million CNY | -22.83% |
| 2023 FY | 217.49 Million CNY | -4.79% |
| 2023 Q1 | 57.91 Million CNY | 113.22% |
| 2022 Q3 | 69.84 Million CNY | 2.48% |
| 2022 Q2 | 68.15 Million CNY | 7.74% |
| 2022 Q1 | 63.25 Million CNY | 84.72% |
| 2022 Q4 | 27.16 Million CNY | -61.11% |
| 2022 FY | 228.42 Million CNY | -14.75% |
| 2021 Q3 | 74.88 Million CNY | -10.39% |
| 2021 Q4 | 34.24 Million CNY | -54.27% |
| 2021 Q2 | 83.56 Million CNY | 11.08% |
| 2021 Q1 | 75.22 Million CNY | -28.94% |
| 2021 FY | 267.92 Million CNY | -13.98% |
| 2020 Q4 | 105.86 Million CNY | 24.63% |
| 2020 FY | 311.46 Million CNY | 53.27% |
| 2020 Q1 | 41.1 Million CNY | 70.87% |
| 2020 Q2 | 79.54 Million CNY | 93.53% |
| 2020 Q3 | 84.94 Million CNY | 6.79% |
| 2019 Q3 | 69.71 Million CNY | 8.67% |
| 2019 Q4 | 24.05 Million CNY | -65.49% |
| 2019 FY | 203.21 Million CNY | 2.94% |
| 2019 Q1 | 45.29 Million CNY | 42.33% |
| 2019 Q2 | 64.15 Million CNY | 41.63% |
| 2018 Q3 | 53.71 Million CNY | -6.29% |
| 2018 Q1 | 54.56 Million CNY | -0.92% |
| 2018 FY | 197.41 Million CNY | -13.52% |
| 2018 Q4 | 31.82 Million CNY | -40.75% |
| 2018 Q2 | 57.31 Million CNY | 5.05% |
| 2017 Q4 | 55.06 Million CNY | -9.82% |
| 2017 Q2 | 59.73 Million CNY | 14.01% |
| 2017 Q3 | 61.06 Million CNY | 2.22% |
| 2017 FY | 228.26 Million CNY | -6.87% |
| 2017 Q1 | 52.39 Million CNY | -34.47% |
| 2016 Q1 | 49.46 Million CNY | -30.91% |
| 2016 Q3 | 54.64 Million CNY | -10.48% |
| 2016 Q4 | 79.96 Million CNY | 46.32% |
| 2016 FY | 245.11 Million CNY | 2.65% |
| 2016 Q2 | 61.04 Million CNY | 23.42% |
| 2015 Q4 | 71.58 Million CNY | 17.71% |
| 2015 Q2 | 56.71 Million CNY | 14.14% |
| 2015 Q1 | 49.68 Million CNY | -8.24% |
| 2015 FY | 238.79 Million CNY | 35.5% |
| 2015 Q3 | 60.81 Million CNY | 7.24% |
| 2014 FY | 176.23 Million CNY | 38.42% |
| 2014 Q2 | 37.14 Million CNY | 6.16% |
| 2014 Q4 | 54.14 Million CNY | 8.37% |
| 2014 Q3 | 49.96 Million CNY | 34.53% |
| 2014 Q1 | 34.98 Million CNY | -34.99% |
| 2013 Q2 | 21.71 Million CNY | -5.62% |
| 2013 FY | 127.31 Million CNY | 41.64% |
| 2013 Q3 | 28.78 Million CNY | 32.56% |
| 2013 Q4 | 53.81 Million CNY | 86.93% |
| 2013 Q1 | 23 Million CNY | -7.71% |
| 2012 Q4 | 24.93 Million CNY | 12.91% |
| 2012 Q1 | 18.84 Million CNY | -25.43% |
| 2012 Q2 | 24.03 Million CNY | 27.54% |
| 2012 Q3 | 22.08 Million CNY | -8.14% |
| 2012 FY | 89.89 Million CNY | 31.77% |
| 2011 Q4 | 25.27 Million CNY | 100.22% |
| 2011 Q2 | 16.17 Million CNY | 14.25% |
| 2011 Q1 | 14.15 Million CNY | -71.4% |
| 2011 FY | 68.21 Million CNY | 38.96% |
| 2011 Q3 | 12.62 Million CNY | -21.95% |
| 2010 Q3 | 13.76 Million CNY | 18.39% |
| 2010 Q1 | 11.66 Million CNY | 0.0% |
| 2010 Q2 | 11.62 Million CNY | -0.32% |
| 2010 Q4 | 49.49 Million CNY | 259.5% |
| 2010 FY | 49.09 Million CNY | 23.67% |
| 2009 FY | 39.69 Million CNY | 52.34% |
| 2008 FY | 26.05 Million CNY | 29.52% |
| 2007 FY | 20.11 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 6.58 Billion CNY | 95.805% |
| Realcan Pharmaceutical Group Co., Ltd. | 948.69 Million CNY | 70.883% |